secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAVEX LIFE SCIENCES CORP. (AVXL)
CIK:        0001314052
Form:       8-K
Filed at:   2026-08-25T12:31:04+00:00
Accession:  0001731122-26-001143
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anavex Q3 net income $7.8M on comp reversal; advances FDA/EMA regulatory plans
------------------------------------------------------------------------------

- Q3 FY2026 net income $7.8M ($0.08/share) vs net loss $13.2M ($0.16/share) in Q3 FY2025.
- Cash $118.3M at June 30, 2026 (vs $102.6M at Sept 30, 2025); funds ops into mid-late FY2028.
- Reversal of $17.4M stock-based comp (G&A $7.5M, R&D $9.9M) from employee terminations, mainly former CEO.
- Submitted all AD clinical data to FDA; FDA Phase 3 AD-005 design talks planned; EMA scientific advice received June 2026.
- Rett Phase 3 RS-005 (~170 pts): FDA meeting requested on pediatric inclusion; Fragile X IND due Sept; 10-Q filings pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/0001731122-26-001143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-001143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer